Genfit stock rallies 20% after hours on data for liver disease drug (GNFT)


Anatomy of human body with liver. 3d illustration

Mohammed Haneefa Nizamudeen

Shares of Genfit (NASDAQ:GNFT) shot up 20% in after-hours trading Monday after the biotech company and partner Ipsen (OTCPK:IPSEY) announced the presentation of positive results from a Phase 3 study of their drug elafibranor in the treatment

Source link

Leave A Reply

Your email address will not be published.